Sopan Pharmaceuticals IPO Guide: A Strategic Investment Opportunity in Nepals Healthcare Sector
16th April 2026, Kathmandu
The Nepali stock market is witnessing another landmark event as Sopan Pharmaceuticals Limited officially opens its Initial Public Offering for the general public.
Sopan Pharmaceuticals IPO Guide
This move marks a significant milestone for the company and provides a unique gateway for retail investors to tap into the growing pharmaceutical industry. Following a successful first phase dedicated to Nepali citizens working abroad, the second phase is now live, inviting the broader public to become stakeholders in this promising enterprise.
Understanding the Sopan Pharmaceuticals IPO Structure
Sopan Pharmaceuticals Limited operates with a total issued capital of NPR 1.716 billion. To facilitate public participation and expansion, the company has allocated 25 percent of its total capital for public issuance. This translates to an offering worth NPR 429 million. In total, the company is issuing 4.249 million shares, each carrying a face value of NPR 100. This standardized pricing ensures that the IPO remains accessible to everyday retail investors across Nepal.
The issuance has been executed in a staged manner to comply with regulatory frameworks and ensure fair distribution. Before opening to the general public, several key groups received their allocations:
Foreign Employed Nepalis: 10 percent of the total public offering, amounting to 429000 shares, was successfully distributed to Nepali workers abroad.
Company Employees: 4 percent or 171600 shares were reserved and distributed among the dedicated staff of the organization.
Mutual Funds: 5 percent or 214500 shares were set aside for mutual investment funds to stabilize the institutional holding.
With these phases complete, the remaining 3474900 shares are now available for the general public to subscribe to, starting from April 16 2026.
Key Dates and Application Details
Timely action is essential for anyone looking to participate in this IPO. The application window is relatively short, and given the high demand for new issues in Nepal, oversubscription is a distinct possibility.
Advertisement
Investors can begin submitting their applications on April 16 2026. The initial deadline for the subscription is set for April 21 2026, though it may be extended until April 30 2026 if the issue is not fully subscribed. However, historically, pharmaceutical IPOs in Nepal tend to close early due to massive retail interest.
For those planning their investment, the bank has set flexible limits. You can apply for a minimum of 10 shares, which requires an investment of NPR 1000. For larger investors, the maximum application limit is set at 11000 shares. This range ensures that both small scale savers and larger individual investors can find a place in the company equity.
How to Apply for the IPO Online
The process for applying has been made highly convenient through digital integration. NMB Capital Limited is serving as the issue and sales manager, bringing professional expertise and reliability to the process.
There are two primary ways to submit your application:
Mero Share Platform: Most investors prefer using the Mero Share website or mobile app. This digital interface allows you to apply from the comfort of your home. Simply log in, navigate to the ASBA section, select Sopan Pharmaceuticals Limited, and enter the number of shares you wish to purchase.
C ASBA Member Banks: You can also visit any authorized bank or financial institution that is a member of the C ASBA system. These institutions are equipped to handle your application and block the required funds in your bank account until the allotment process is finalized.
Why Invest in Sopan Pharmaceuticals
The pharmaceutical sector in Nepal is currently in a phase of rapid development. As the country seeks to become more self reliant in medicine production, companies like Sopan Pharmaceuticals are positioned at the forefront of this industrial shift. Investing in an IPO is not just about buying shares; it is about owning a piece of a company that contributes to the national healthcare infrastructure.
However, every investor should exercise due diligence. Before applying, it is wise to review the financial fundamentals of the company, its projected growth, and the overall market conditions. While the pharmaceutical industry offers defensive growth qualities, equity investments always carry a level of market risk.
Conclusion
The Sopan Pharmaceuticals IPO represents a well regulated and structured opportunity for the public to diversify their portfolios. With a clear allocation strategy and a reputable issue manager like NMB Capital, the process is transparent and investor friendly. Make sure to have your CRN number ready and your Mero Share account active to participate before the deadline on April 21 2026. This could be your chance to join the growth story of one of Nepals emerging healthcare leaders.
For More: Sopan Pharmaceuticals IPO Guide
